EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

QuantiFERON-TB Gold Plus for screening and monitoring latent tuberculosis infection in spondyloarthritis patients

Zehra Ozsoy, Adem Ozdemir, Mustafa Ekici, Emre Bilgin, Asena Eken, Zeynep Saribas, Ahmet C Inkaya, Deniz Koksal, Burcin Sener, Ihsan Ertenli, Omer Karadag, Levent Kilic

The Journal of Infection in Developing Countries · 2025

DOI: 10.3855/jidc.21027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2025. Verfasst von Zehra Ozsoy und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey. Hauptthemen laut MEDLINE: Latent Tuberculosis, Interferon-gamma Release Tests, Spondylarthritis, Mass Screening. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The optimal frequency of rescreening for latent tuberculosis infection (LTBI) in patients with inflammatory arthritis on biologic/targeted-synthetic disease modifying anti-rheumatic drugs (b/ts-DMARDs) is uncertain. We aimed to evaluate the impact of LTBI re-screening using the QuantiFERON-TB Gold Plus (QFT-Plus; QIAGEN, Germantown, USA) test method and to assess the frequency of re-screening in real-life spondyloarthritis (SpA) patients on b/ts-DMARDs. Methodology: This study focused on patients with SpA who were scheduled for b/ts-DMARDs therapy and underwent QFT-Plus testing to screen for LTBI. The study analyzed whether QFT-Plus test negative patients underwent sequential QFT-Plus tests during follow-up and the timing of these tests. Cases of tuberculosis (TB) reactivation were documented, and the clinical status of affected patients were recorded.

Results

Of the 801 patients included in the study, the QFT-Plus tests were negative in 701 (87.5%), positive in 89 (11.1%), and indeterminate in 11 (1.3%) patients. The median follow-up of patients with initial QFT-Plus test negative was 33.6 months (min–max: 3–76.3). Follow-up tests were carried out on only 59 (8.4%) of these 701 patients. Of the rescreened 59 patients, 56 had negative results, 3 had positive results. TB was developed in only 2 (0.25%) of the 801 patients during follow-up.

Conclusions

Assessment of LTBI in patients with SpA using interferon-gamma release assays (IGRAs) test is rational. Performance of annual testing of IGRAs in patients who were QFT negative was low in our SpA cohort. National and international guidelines may need to be updated to reflect real-world data and clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Latent TuberculosisInterferon-gamma Release TestsSpondylarthritisMass ScreeningHumansMaleFemaleAdultMiddle AgedAntirheumatic AgentsYoung Adult

Stichwörter der Autor:innen

IGRAbiological/targeted DMARDsrescreeningspondyloarthritistuberculosis

Substanzen

Antirheumatic Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey .
  • Department of Medical Microbiology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Department of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Department of Infectious Disease, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Department of Chest Diseases, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Zitieren

APA

Ozsoy, Z., Ozdemir, A., Ekici, M., Bilgin, E., Eken, A., Saribas, Z., Inkaya, A. C., Koksal, D., Sener, B., Ertenli, I., Karadag, O., & Kilic, L. (2025). QuantiFERON-TB Gold Plus for screening and monitoring latent tuberculosis infection in spondyloarthritis patients. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.21027

Vancouver

Ozsoy Z, Ozdemir A, Ekici M, Bilgin E, Eken A, Saribas Z, et al. QuantiFERON-TB Gold Plus for screening and monitoring latent tuberculosis infection in spondyloarthritis patients. The Journal of Infection in Developing Countries. 2025. doi:10.3855/jidc.21027

BibTeX
@article{Ozsoy2025,
  author = {Ozsoy, Zehra and Ozdemir, Adem and Ekici, Mustafa and Bilgin, Emre and Eken, Asena and Saribas, Zeynep and Inkaya, Ahmet C and Koksal, Deniz and Sener, Burcin and Ertenli, Ihsan and Karadag, Omer and Kilic, Levent},
  title = {QuantiFERON-TB Gold Plus for screening and monitoring latent tuberculosis infection in spondyloarthritis patients},
  journal = {The Journal of Infection in Developing Countries},
  year = {2025},
  doi = {10.3855/jidc.21027}
}
Kostenlos starten →